The document discusses in silico analysis and drug design to inhibit entry of the Ebola virus through the Niemann Pick C1 protein. Four FDA-approved drugs were studied that inhibit Ebola virus entry through late-stage inhibition. Docking studies showed BM15766 had the highest binding score to the NPC1 receptor. Scaffold modeling was then used to design 375 scaffolds, with scaffold 165 having the best score and proposed as a potential new antiviral drug.